Celebrex (Celecoxib) Antitrust Litigation
Berger Montague represented a class of direct purchasers of brand and generic Celebrex (celecoxib) in an action alleging that Pfizer, in violation of the Sherman Act, improperly obtained a patent for Celebrex from the U.S. Patent and Trademark Office in a scheme to unlawfully extend patent protection and delay market entry of generic versions of Celebrex. Plaintiffs alleged that Pfizer’s conduct caused the class overcharge damages.
After more than three years of litigation and on the eve of trial, the direct purchaser class settled with Pfizer. Pfizer agreed to pay $94,000,000 in the settlement. The settlement was given final approval on April 18, 2018.
LEAD ATTORNEYS: David F. Sorensen, Ellen T. Noteware, Zachary D. Caplan